Compare Stocks: GRCE, VTVT, NRXP, and VANI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRCE Grace Therapeutics	$2.08 +0.5%	$2.35	$1.79 ▼ $5.18	$33.69M	0.37	224,611 shs	177,500 shs
NRXP NRx Pharmaceuticals	$3.15 +1.0%	$3.99	$1.62 ▼ $5.05	$113.03M	2.19	825,922 shs	1.14 million shs
VANI Vivani Medical	$1.28 -1.5%	$1.27	$0.92 ▼ $1.92	$112.11M	2.33	1.01 million shs	33,535 shs
VTVT vTv Therapeutics	$32.35 -1.0%	$33.39	$14.00 ▼ $44.00	$128.72M	0.25	85,869 shs	136,838 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRCE Grace Therapeutics	+0.48%	-10.73%	-7.14%	-11.11%	-29.97%
NRXP NRx Pharmaceuticals	+0.96%	-16.00%	-18.39%	+1.94%	+12.10%
VANI Vivani Medical	-1.54%	0.00%	+4.07%	-5.88%	-10.49%
VTVT vTv Therapeutics	-1.01%	+5.27%	-7.70%	+2.11%	+123.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRCE Grace Therapeutics	$2.08 +0.5%	$2.35	$1.79 ▼ $5.18	$33.69M	0.37	224,611 shs	177,500 shs
NRXP NRx Pharmaceuticals	$3.15 +1.0%	$3.99	$1.62 ▼ $5.05	$113.03M	2.19	825,922 shs	1.14 million shs
VANI Vivani Medical	$1.28 -1.5%	$1.27	$0.92 ▼ $1.92	$112.11M	2.33	1.01 million shs	33,535 shs
VTVT vTv Therapeutics	$32.35 -1.0%	$33.39	$14.00 ▼ $44.00	$128.72M	0.25	85,869 shs	136,838 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRCE Grace Therapeutics	+0.48%	-10.73%	-7.14%	-11.11%	-29.97%
NRXP NRx Pharmaceuticals	+0.96%	-16.00%	-18.39%	+1.94%	+12.10%
VANI Vivani Medical	-1.54%	0.00%	+4.07%	-5.88%	-10.49%
VTVT vTv Therapeutics	-1.01%	+5.27%	-7.70%	+2.11%	+123.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRCE Grace Therapeutics	2.00	Hold	$6.00	188.46% Upside
NRXP NRx Pharmaceuticals	2.50	Moderate Buy	$38.25	1,114.29% Upside
VANI Vivani Medical	2.25	Hold	$3.75	192.97% Upside
VTVT vTv Therapeutics	2.63	Moderate Buy	$56.67	75.17% Upside

Current Analyst Ratings Breakdown

Latest GRCE, VTVT, NRXP, and VANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	VTVT vTv Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$49.00 ➝ $57.00
7/7/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	VTVT vTv Therapeutics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$67.00
6/23/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/23/2026	VANI Vivani Medical	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/11/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2026	VANI Vivani Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/18/2026	VTVT vTv Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
5/13/2026	VTVT vTv Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$4.13 per share	N/A
NRXP NRx Pharmaceuticals	$1.23M	92.78	N/A	N/A	($0.54) per share	-5.83
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.20 per share	N/A
VTVT vTv Therapeutics	$1.02M	124.96	N/A	N/A	$16.36 per share	1.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRCE Grace Therapeutics	-$7.79M	-$0.48	N/A	N/A	N/A	N/A	-14.45%	-13.58%	8/11/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$1.09	N/A	5.34	N/A	N/A	N/A	-202.92%	8/17/2026 (Estimated)
VANI Vivani Medical	-$26.61M	-$0.40	N/A	N/A	N/A	N/A	-264.04%	-79.85%	8/12/2026 (Estimated)
VTVT vTv Therapeutics	-$26.97M	-$0.93	N/A	N/A	N/A	N/A	3.96%	2.86%	8/11/2026 (Estimated)

Latest GRCE, VTVT, NRXP, and VANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.09	N/A	N/A	N/A	$1.75 million	N/A
8/12/2026	Q2 2026	VANI Vivani Medical	-$0.08	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	N/A	N/A	N/A	$0.40 million	N/A
8/11/2026	Q2 2026	VTVT vTv Therapeutics	-$0.97	N/A	N/A	N/A	$0.33 million	N/A
6/18/2026	Q4 2026	GRCE Grace Therapeutics	-$0.24	-$0.07	+$0.17	-$0.06	$0.90 million	N/A
5/15/2026	Q1 2026	NRXP NRx Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	$19.43 million	$1.07 million
5/13/2026	Q1 2026	VANI Vivani Medical	-$0.08	-$0.08	N/A	-$0.08	N/A	N/A
5/13/2026	Q1 2026	VTVT vTv Therapeutics	$0.21	$1.65	+$1.44	$1.65	$20.00 million	$36.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRCE Grace Therapeutics	N/A	8.10	8.10
NRXP NRx Pharmaceuticals	N/A	0.29	0.29
VANI Vivani Medical	N/A	3.18	3.18
VTVT vTv Therapeutics	N/A	14.36	14.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRCE Grace Therapeutics	6.08%
NRXP NRx Pharmaceuticals	4.27%
VANI Vivani Medical	6.78%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
GRCE Grace Therapeutics	11.10%
NRXP NRx Pharmaceuticals	6.40%
VANI Vivani Medical	53.30%
VTVT vTv Therapeutics	5.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRCE Grace Therapeutics	N/A	16.27 million	14.47 million	N/A
NRXP NRx Pharmaceuticals	2	36.23 million	33.91 million	Optionable
VANI Vivani Medical	20	86.24 million	40.27 million	Optionable
VTVT vTv Therapeutics	9	3.94 million	3.70 million	Not Optionable

GRCE, VTVT, NRXP, and VANI Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving Average - Here's What Happened

1 hour ago | marketbeat.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $56.67 Consensus Target Price from Analysts

July 29 at 2:58 AM | americanbankingnews.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 28, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts

July 24, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average - Here's Why

July 24, 2026 | marketbeat.com

vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says

July 16, 2026 | marketbeat.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 2, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 2, 2026 | globenewswire.com

vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next

May 17, 2026 | finance.yahoo.com

Why vTv Therapeutics Inc.’s (VTVT) Stock Is Down 8.13%

May 16, 2026 | aaii.comA

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

May 15, 2026 | zacks.com

vTv Therapeutics Expands At-The-Market Share Program Capacity

May 13, 2026 | tipranks.com

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | globenewswire.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 8, 2026 | globenewswire.com

vTv Therapeutics to Participate in Upcoming May Investor Conferences

May 7, 2026 | globenewswire.com

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

April 20, 2026 | zacks.com

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 7, 2026 | globenewswire.com

vTv Therapeutics, Inc. Class A

April 6, 2026 | edition.cnn.com

Wall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a Bet

April 2, 2026 | zacks.com

vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements

March 17, 2026 | insidermonkey.com

Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade

March 17, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, VTVT, NRXP, and VANI Company Descriptions

Grace Therapeutics NASDAQ:GRCE

$2.08 +0.01 (+0.48%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$2.08 0.00 (-0.24%)

As of 07/31/2026 07:34 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

NRx Pharmaceuticals NASDAQ:NRXP

$3.15 +0.03 (+0.96%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.24 +0.10 (+3.02%)

As of 07/31/2026 07:59 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Vivani Medical NASDAQ:VANI

$1.28 -0.02 (-1.54%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.30 +0.01 (+1.17%)

As of 07/31/2026 07:34 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

vTv Therapeutics NASDAQ:VTVT

$32.35 -0.33 (-1.01%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$32.22 -0.13 (-0.42%)

As of 07/31/2026 04:10 PM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCE, VTVT, NRXP, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCE, VTVT, NRXP, and VANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCE, VTVT, NRXP, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, VTVT, NRXP, and VANI Company Descriptions

Grace Therapeutics NASDAQ:GRCE

NRx Pharmaceuticals NASDAQ:NRXP

Vivani Medical NASDAQ:VANI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GRCE, VTVT, NRXP, and VANI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GRCE, VTVT, NRXP, and VANI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GRCE, VTVT, NRXP, and VANI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE, VTVT, NRXP, and VANI Company Descriptions

Grace Therapeutics NASDAQ:GRCE

NRx Pharmaceuticals NASDAQ:NRXP

Vivani Medical NASDAQ:VANI

vTv Therapeutics NASDAQ:VTVT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools